Although the precise mechanisms of action by which CRBN and thalidomide affect Syk phosphorylation have not been clearly elucidated, the thalidomide derivative lenalidomide reduces Syk phosphorylation by decreasing lymphocyte-specific-protein-kinase (Lck) phosphorylation in chronic lymphocytic leukemia cells [45]. Here, SYK is linked to B-cell chronic lymphocytic leukemia.